Search the Newsreel

Codexis (CDXS) investor Laurence Lytton discloses 5.2% beneficial stake in shares

Laurence W. Lytton has reported a beneficial ownership of 5,592,972 shares of Codexis, Inc. (CDXS) common stock, which represents a 5.2% stake in the company. This disclosure was made via a SCHEDULE 13G/A filing with the SEC, indicating an increase in his holdings above …

Codexis, Inc. Stock 12‑Month Price Target Cut to $6.5, Implies 339% Upside

The average 12-month price target for Codexis, Inc. (CDXS) stock has been slightly cut from $6.58 to $6.5 by 6 analysts, with forecasts ranging from $2 to $11. This updated target implies a significant potential upside of approximately 339% based on the August 11 …

Codexis, Inc. Q2 2026 Earnings Call Summary

Codexis, Inc. reported a return to growth in its pharma biocatalysis business, driven by new product approvals and a significant label expansion. The company is strategically focusing on industrializing its ECOsynthesis platform to address projected siRNA demand, backed by recent equity financing and improved …

Codexis narrows Q2 loss, raises $25M to fund GMP expansion

Codexis Inc. (NASDAQ: CDXS) significantly narrowed its Q2 2026 net loss to $12.0 million and beat EPS estimates, though revenue slightly declined. The company also secured $25 million in equity financing, extending its cash runway until 2028 and enabling the expansion of its ECO …

Codexis outlines $72M-$76M 2026 revenue as it plans ~$25M GMP facility build-out

Earnings Call Insights: Codexis (CDXS) Q2 2026 MANAGEMENT VIEW * CEO Alison Moore said Codexis delivered “solid financial results for the second quarter of 2026 with revenue of $14.9 million” and highlighted that a financing “resulted in a capital raise of $25 million of …

Codexis (NASDAQ:CDXS) Issues Earnings Results

Earnings call transcript: Codexis beats Q2 2026 estimates as shares rise after hours

Codexis, Inc. reported a return to growth in its pharma biocatalysis business, driven by new product approvals and a significant label expansion. The company is strategically focusing on industrializing its ECOsynthesis platform to address projected siRNA demand, backed by recent equity financing and improved …

Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates

CODEXIS ($CDXS) Releases Q2 2026 Earnings, Stock Rises

Codexis Reports Second Quarter 2026 Financial Results

Codexis, Inc. reported its second-quarter 2026 financial results, with total revenues of $14.9 million. The company reiterated its full-year 2026 financial guidance, projecting revenues between $72 million and $76 million. Key highlights include advancements in RNA therapeutic manufacturing, a successful equity capital raise of …

Codexis Inc (CDXS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Codexis Inc (CDXS), highlighting its current earnings forecast score of 8.00 and an average price target of $7.00. Based on ratings from 7 analysts, the stock has a "Buy" trend with a significant upside space. The company's …

Codexis (CDXS) Projected to Release Earnings on Tuesday

Codexis (CDXS) is anticipated to release its Q2 2026 earnings after the market closes on Tuesday, August 11th. Analysts project a loss of $0.17 per share on revenue of approximately $13.8 million. The biotechnology company previously beat expectations in Q1, reporting a $0.10-per-share loss …

Codexis, Inc. Revenue Breakdown – NASDAQ:CDXS

Codexis, Inc. (NASDAQ: CDXS) generated $70.39 million in revenue last year, primarily from its Biocatalysts, Pharmaceutical Intermediates, and Codex Biocatalyst Panels and Kits segment. This represented an increase from the $59.34 million reported the previous year. The United States was the largest contributor to …

Codexis Inc (CDXS) Financial Health: Profitability & Balance Sheet Analysis

Codexis Inc (CDXS) has a strong financial health score of 8.88, ranking 25th in its industry. The company reported a 102.15% year-over-year increase in its latest quarterly revenue and a 57.93% increase in net profit. However, several detailed financial metrics related to cash and …

Codexis appoints David Butler to strategic advisory board

Codexis, Inc. (NASDAQ:CDXS) has announced the appointment of David Butler to its Strategic Advisory Board. Butler brings over two decades of experience in the oligonucleotide field, having previously served as Chief Technology Officer at Hongene Biotech Corporation and in leadership roles at Wave Life …

20-Year Oligonucleotide Veteran David Butler Joins Codexis Board

Codexis (Nasdaq: CDXS) has appointed Dr. David Butler, a veteran with over 20 years of experience in oligonucleotide therapeutics, to its Strategic Advisory Board. Dr. Butler will provide critical technical guidance and industry expertise to support Codexis' growth and innovation in complex oligonucleotide therapeutics …

Codexis, Inc. Revenue Breakdown – BX:4QK

Codexis, Inc. (BX:4QK) generated 55.80 million CHF in revenue last year, primarily from its Biocatalysts, Pharmaceutical Intermediates, and Codex Biocatalyst Panels and Kits segment. This revenue marks an increase from 53.90 million CHF the previous year. The United States was the largest contributor to …

Codexis Inc (CDXS) Institutional Confidence

The article analyzes the institutional confidence score for Codexis Inc (CDXS), noting its current score of 7.00, which ranks 80 out of 385 in the Biotechnology & Medical Research industry. It highlights that the institutional shareholding proportion is 73.00%, a 13.55% decrease quarter-over-quarter. Bill …

Form 424B5 Codexis Inc For: 24 July By Investing.com

This article from Investing.com reports on a Form 424B5 filing by Codexis Inc on July 24th. The brief news item indicates that Codexis Inc's stock symbol is CDXS, which was down 2.00% at the time of publication. The page also features current market data …

Codexis, Inc. (CDXS) investors report 7.3% stake in 7.85M shares

Telemark Asset Management, LLC, Telemark Fund, LP, and Colin S. McNay have jointly reported beneficial ownership of 7,846,411 shares of Codexis, Inc. (CDXS) common stock, representing a 7.3% stake. This ownership includes shared voting and dispositive power, calculating the percentage based on 107,561,409 outstanding …

Codexis to Report Second Quarter 2026 Financial Results on August 11

Codexis, Inc. (NASDAQ: CDXS) announced it will report its Q2 2026 financial results on Tuesday, August 11, 2026, after market close. The company will host a conference call and webcast at 4:30 pm Eastern Time to discuss the results and provide a business update, …

Codexis schedules 4:30 p.m. ET webcast after Aug. 11 close

Codexis (NASDAQ: CDXS) announced it will report its Q2 2026 financial results on Tuesday, August 11, 2026, after the market closes. Management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss results and provide a business update, with access …

Codexis Inc (CDXS) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Codexis Inc (CDXS), rating its overall risk score at 2.99, which ranks it 167 out of 386 in the Biotechnology & Medical Research industry. The company's high beta of 2.50 suggests significant volatility, with the stock likely …

Codexis Inc (CDXS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Codexis Inc (CDXS), detailing its price momentum score, current support and resistance levels, and signals from various technical indicators and moving averages. While the stock's price momentum is 5.56, suggesting it's suitable for range-bound swing trading, most …

CDXS|Codexis Inc|Price:1.480|Chg%:-0.510

Codexis Inc. is a provider of enzymatic solutions, leveraging its CodeEvolver technology to develop high-performance enzymes for pharmaceutical manufacturing and RNA-based therapeutics. The company's stock, CDXS, is currently priced at $1.480, reflecting a significant drop. This article provides a detailed company profile, including financial …

CDXS Stock Falls As Codexis Prices Dilutive Share Offering

Codexis Inc. (CDXS) shares fell significantly after the company announced a dilutive public offering of 16.7 million new shares at $1.50 each to raise about $23.1 million. The move is intended to fund working capital, R&D, and general corporate purposes, extending the company's financial …

Codexis, Inc. Revenue Breakdown – TRADEGATE:4QK

Codexis, Inc. (TRADEGATE:4QK) generated €59.93 million in revenue last year, primarily from its Biocatalysts, Pharmaceutical Intermediates, and Codex Biocatalyst Panels and Kits segment. This represented an increase from €57.33 million the previous year. The majority of the revenue, €37.07 million, originated from the United …

Codexis Market Sentiment

This article analyzes market sentiment for Codexis (CDXS) based on analyst consensus, short interest, options flow, and insider activity. Analysts have an "Overweight" consensus with an average price target significantly above the current stock price, while options flow indicates a bearish sentiment due to …

Codexis Expects Offering to Close on or About July 27 >CDXS

Codexis anticipates the closing of its offering will occur on or about July 27. This brief announcement provides a definitive timeline for the completion of the company's offering under the stock symbol CDXS.

CDXS Stock Slides As Dilutive Offering Reshapes Trading Setup

Codexis Inc. (CDXS) shares have slid by over 22% following the announcement of an underwritten public offering of 16.7 million new common shares at $1.50 each, with an option for underwriters to purchase an additional 2.5 million shares. This dilutive offering, while extending the …

At a glance: stocks gapping down premarket

[Wall Street-Street Sign] P_Wei/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-down moves before the bell Friday. Stock index futures were higher on Friday as the stock market hoped to recover from Thursday's selloff. COMPANY MOVE Codexis (CDXS …

Codexis prices 16,666,667-share common stock offering at $1.5 per share

Codexis has priced an underwritten public offering of 16,666,667 common shares at $1.5 each, expecting net proceeds of approximately $23.1 million. The closing is targeted for around July 27, 2026, with underwriters holding a 30-day option to purchase additional shares. The company plans to …

Codexis Prices Public Offering Of 16.67 Mln Shares At $1.50/Shr; Stock Drops 19%

(RTTNews) - Codexis, Inc. (CDXS), a provider of enzymatic solutions, announced the pricing of its public offering of 16.67 million shares at a price of $1.50 per share. The company expects net proceeds of approximately $23.1 million, which it intends to use for working …